News

CMS’ Quality Payment Program launched in 2016 as part of MACRA. Here’s what’s in store for Year 2.

PBMs partnering with pharmacies and drug makers may have a solution to nonadherence due to high pharma costs.

The first therapy based on gene transfer has been approved by the FDA. What’s next for healthcare executives?

Hospitals innovatively improve the patient experience as the industry shifts to value-based care.

There are several possible reasons that breastfeeding may influence breast cancer risk, according to the American Institute of Cancer Research. Find out what they are.

New research shows that these certain patients with breast cancer can benefit from genetic testing for all breast cancer genes.

As more specialty drugs are approved, cost control strategies are key.

In an intense healthcare era, there’s no “one-size-fits-all" approach to managing, but here are four things a fearless leader must do.

Political uncertainty plagues new payment arrangement, but private payers embrace new model.

Experts share how the declaration could affect how the opioid epidemic is managed.

A top-selling diabetes drug has gained a cardiovascular indication from FDA.

New biosimilars may harm the sales of this autoimmune blockbuster.

Here’s what industry experts think after Cigna’s business model shift.

A new University of California, San Diego-led review has interesting findings about diabetes costs, patient care models and medication therapy.

A new UC Berkeley study has surprising findings about reference pricing and patient drug selection.

Cigna publication project takes a page out of the big pharma and medical technology playbook.

Allegheny Health Network’s Susan Manzi, MD, MPH, discusses the healthcare needs of patients with lupus and other autoimmune disorders.

Administrative costs are a huge burden in healthcare, but there are several process changes that can result in huge savings.

The concepts that power cognitive computing and AI have grown to include substantial healthcare advancements.

Today there are nearly 67,000 genetic tests. With so many tests available, it can be difficult for MCOs to determine what to cover.

FDA approved a targeted new drug to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

An FDA committee will review prescription opioid products containing hydrocodone or codeine to treat coughs in children.

As President Trump declares the opioid epidemic “a national emergency,” a new opioid management program from Express Scripts will limit the number and strength of opioid drugs to first-time patients.

As legislative discussions begin regarding the reauthorization of CHIP, it is imperative to keep in mind how proposed cuts could be detrimental to the health and future of our nation’s children.

A National Business Group on Health survey finds that with costs continuing to rise, employers are shifting control efforts to how healthcare is delivered and paid for.

A new report by the Blue Cross Blue Shield Association has eye-opening findings about diabetes prevalence, severity and cost.

Consumer and provider expectations have changed as a result of the digital economy. Here are four reasons why payers need to start migrating their businesses in that direction.

Pharmacy and medical organizations lauded a new class action lawsuit against CVS Health and Walgreens, alleging the two pharmacy chains colluded with pharmacy benefit managers (PBMs) to drive up the cost of generic drugs.